Aileron

Aileron Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class medicines for orphan pulmonary diseases. Following its 2023 merger with Lung Therapeutics, the company's lead program is LTI-03, a synthetic peptide derived from caveolin-1 designed to treat idiopathic pulmonary fibrosis (IPF) by protecting alveolar epithelial cells and inhibiting fibrosis. The company is also developing LTI-01, a recombinant pro-enzyme currently in Phase 2 clinical trials for the treatment of loculated pleural effusion. Aileron's strategy leverages its expertise in peptide and protein therapeutics to address significant unmet needs in respiratory medicine. The company is headquartered in Austin, Texas, and is listed on the NASDAQ stock exchange under the symbol ALRN.